Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells.

Nutrition and cancer - 1 Jan 2013

Ghasemi Reza, Ghaffari Seyed H, Momeny Majid, Pirouzpanah Saeed, Yousefi Mehdi, Malehmir Mohsen, Alimoghaddam Kamran, Ghavamzadeh Ardeshir

Abstract excerpt

Hepatocellular carcinoma (HCC) is the most common sort of primary liver malignancy with poor prognosis. This study aimed at examining the effects of silibinin (a putative antimetastatic agent) on some transcriptional markers mechanistically related to HCC recurrence and metastasis in HepG-2 [hepatitis B virus (HBV)-negative and P53 intact) and PLC/PRF/5 (HBV-positive and P53 mutated) cells. The expression of 27...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Hep G2 Cells

Share to Hepatitis B virus

Share to Liver Neoplasms

Share to Matrix Metalloproteinase 2

Share to Matrix Metalloproteinase 9

Source

Identifiers

PMID: 23659451
DOI: 10.1080/01635581.2013.770043

Genes

ANGPT2
CCR6
CCR7
CXCR4
GLI2
PAK1
PROX1
RHOA
SPINK1
STMN1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells.PMID 23659451Read ↗

Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An OverviewSemantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

Dual Effects of Silibinin on Human Pancreatic Cancer CellsSemantic proximity Read ↗

APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma through MEK/ERK and CREB/Bcl-xl pathwaysSemantic proximity Read ↗

Dual role of ANGPTL8 in promoting tumor cell proliferation and immune escape during hepatocarcinogenesisSemantic proximity Read ↗

Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase‐plasminogen activator and matrix metalloproteinase‐2Semantic proximity Read ↗

Effects of Pyrrole-Imidazole Polyamides Targeting Human TGF-β1 on the Malignant Phenotypes of Liver Cancer Cells.Semantic proximity Read ↗

Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 proteinSemantic proximity Read ↗

Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular CarcinomaSemantic proximity Read ↗

RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinomaSemantic proximity Read ↗

Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.Semantic proximity Read ↗

Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.